UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 001-36365 SCYNEXIS, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organiza ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION SCYNEXIS, Inc. (Exact name of registrant as specified in its charter) WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Delaware 56-2181648 (State or other jurisdiction of incorporation or organization) 1 Evert ...

SCYNEXIS, Inc. (NASDAQ:SCYX) Q3 2022 Results Conference Call November 9, 2022 8:30 AM ET Company Participants Debbie Etchison - Communications & IR Dr. Marco Taglietti - President & CEO Dr. David Angulo - Chief Medical Officer Ivor Macleod - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Michael Higgins - Ladenburg Thalmann Shubhendu Sen Roy - Brookline Capital Markets Operator Good morning, and welcome to the SCYNEXIS Third Quarter 2022 Earnings Conference Call. [Operator Instruc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended SEPTEMBER 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 001-36365 SCYNEXIS, Inc. (Exact name of registrant as specified in its charter) Delaware 56-2181648 (State or other jurisdiction of i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Commission File Number 001-36365 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended JUNE 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to SCYNEXIS, Inc. (Exact name of registrant as specified in its charter) Delaware 56-2181648 (State or other jurisdiction of incorp ...

SCYNEXIS, Inc. (NASDAQ:SCYX) Q2 2022 Results Conference Call August 15, 2022 8:30 AM ET Company Participants Debbie Etchison - Communications and IR Dr. Marco Taglietti - President and CEO Christine Coyne - Chief Commercial Officer Dr. David Angulo - Chief Medical Officer Larry Hoffman - Interim CFO Conference Call Participants Carvey Leung - Cantor Fitzgerald Farhana Sakloth - Ladenburg Thalmann Oren Livnat - H.C. Wainwright Kumar Raja - Brookline Capital Markets Steve Brozak - WBB Securities Operator Ladi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended MARCH 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 001-36365 SCYNEXIS, Inc. (Exact name of registrant as specified in its charter) Delaware 56-2181648 (State or other jurisdiction of incor ...

SCYNEXIS, Inc. (NASDAQ:SCYX) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Marco Taglietti – President and Chief Executive Officer Christine Coyne – Chief Commercial Officer Dr. David Angulo – Chief Medical Officer Lawrence Hoffman – Interim Chief Financial Officer Debbie Etchison – Executive Director, Communications Conference Call Participants Michael Higgins – Ladenburg Thalmann Wayne Buchan – Cantor Fitzgerald Oren Livnat – H.C. Wainwright Operator Greetings and welcome t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36365 SCYNEXIS, Inc. (Exact name of registrant as specified in its charter) Delaware 56-2181648 (State or other jurisdiction of incor ...

SCYNEXIS, Inc. (NASDAQ:SCYX) Q4 2021 Earnings Conference Call March 29, 2022 8:30 AM ET Company Participants Debbie Etchison - Executive Director, Communications Marco Taglietti - President and Chief Executive Officer Christine Coyne - Chief Commercial Officer David Angulo - Chief Medical Officer Lawrence Hoffman - Interim Chief Financial Officer Conference Call Participants Carvey Leung - Cantor Fitzgerald Michael Higgins - Ladenburg Thalmann Oren Livnat - H.C. Wainwright Steve Brozak - WBB Securities Kuma ...